missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ LGI1 Monoclonal Antibody (N283/7)
Description
1 μg/mL of MA5-27652 was sufficient for detection of LGI1 in 20 μg of rat brain lysate by colorimetric immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody. Detects approximately 60kDa. This antibody was formerly sold as clone S283-7.
The leucine-rich, glioma inactivated gene 1 (LGI1) was first identified as a candidate tumor suppressor gene for glioma and may play a role in other cancers. LGI1 is a member of a family of highly related proteins containing leucine-rich repeats (LRRs) which are highly similar to other transmembrane signaling molecules and receptors. LGI1 serves as a ligand to ADAM22, a metalloprotease localized at the synapse. Mutations in LGI1 account for nearly half of autodominant lateral temporal epilepsy (ADTLE), an epileptic syndrome characterized by focal seizures with predominant auditory symptoms. Two isoforms of LGI1 are known to exist.
Specifications
Specifications
| Antigen | LGI1 |
| Applications | Immunohistochemistry (PFA fixed), Western Blot, Immunocytochemistry |
| Classification | Monoclonal |
| Clone | N283/7 |
| Concentration | 1 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 50% glycerol and 0.1% sodium azide; pH 7.4 |
| Gene | LGI1 |
| Gene Accession No. | O95970, Q8K4Y5, Q9JIA1 |
| Gene Alias | ADLTE; ADPAEF; ADPEAF; BB130740; EPITEMPIN; Epitempin 1; Epitempin-1; EPT; ETL1; IB1099; leucine rich glioma inactivated 1; leucine-rich glioma inactivated 1; leucine-rich glioma-inactivated protein 1; leucine-rich repeat LGI family, member 1; leucine-rich, glioma inactivated 1; LGI1; OTTHUMP00000020121; OTTHUMP00000020122; UNQ775/PRO1569 |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?